Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Vergent Bioscience Secures $21.5M Series B

2022-10-04
MINNEAPOLIS, MN, Vergent Bioscience, a clinical-stage biotechnology company, announced the close of a $21.5 million Series B financing.
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced the close of a $21.5 million Series B financing.

Orlando Health Ventures led the financing with significant participation from new investors Intuitive Surgical, Inc., Windham Venture Partners, and Rex Health Ventures, as well as additional investment from existing investors Spring Mountain Capital and Colle Capital. The Series B funding brings the total raised by Vergent to date to $34 million.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors